NOVAVAX, INC. (NVAX) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

Third Quarter Financial Results

On November 9, 2016, Novavax, Inc. (the Company) issued a press
release announcing the Companys financial results for the quarter
ended September 30, 2016 and provided an update for investors and
presented information relating to its ongoing clinical
development programs (the Investor Presentation). A copy of the
press release and Investor Presentation are attached as Exhibits
99.1 and 99.2 to this Current Report on Form 8-K and incorporated
into this Item 2.02 by reference. The Investor Presentation is
available on the Companys website at www.novavax.com under
Investors.

The information in Items 2.02, and 9.01 of this Form 8-K
(including Exhibits 99.1 and 99.2) shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act except as expressly set forth by
specific reference in such a filing.

Cautionary Note Regarding Forward-Looking
Statements.The press release and Investor
Presentation contain forward-looking statements that involve
certain risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by these
statements. Please refer to the cautionary notes contained in the
press release Investor Presentation regarding these
forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

About NOVAVAX, INC. (NVAX)